Regen Financial Statements From 2010 to 2024

RGBPP Stock  USD 0.08  0.02  19.60%   
Regen BioPharma financial statements provide useful quarterly and yearly information to potential Regen BioPharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Regen BioPharma financial statements helps investors assess Regen BioPharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regen BioPharma's valuation are summarized below:
Regen BioPharma does not presently have any trending fundamental ratios for analysis.
Check Regen BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regen BioPharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Regen financial statements analysis is a perfect complement when working with Regen BioPharma Valuation or Volatility modules.
  
This module can also supplement various Regen BioPharma Technical models . Check out the analysis of Regen BioPharma Correlation against competitors.

Regen BioPharma Company Return On Asset Analysis

Regen BioPharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Regen BioPharma Return On Asset

    
  -0.76  
Most of Regen BioPharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regen BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Regen BioPharma has a Return On Asset of -0.7581. This is 91.34% lower than that of the Healthcare sector and 96.79% lower than that of the Biotechnology industry. The return on asset for all United States stocks is notably higher than that of the company.

Regen BioPharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Regen BioPharma's current stock value. Our valuation model uses many indicators to compare Regen BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regen BioPharma competition to find correlations between indicators driving Regen BioPharma's intrinsic value. More Info.
Regen BioPharma is currently regarded as top stock in return on asset category among its peers. It is rated second in profit margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regen BioPharma's earnings, one of the primary drivers of an investment's value.

About Regen BioPharma Financial Statements

Regen BioPharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Regen BioPharma investors may analyze each financial statement separately, they are all interrelated. The changes in Regen BioPharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Regen BioPharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California. Regen Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Pair Trading with Regen BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regen BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regen BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Regen Pink Sheet

  0.42BRK-A Berkshire HathawayPairCorr
  0.39PLTR Palantir Technologies Aggressive PushPairCorr
The ability to find closely correlated positions to Regen BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regen BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regen BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regen BioPharma to buy it.
The correlation of Regen BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regen BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regen BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regen BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Regen Pink Sheet Analysis

When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.